AbbVie Inc (ABBV)vsMyriad Genetics Inc (MYGN)
ABBV
AbbVie Inc
$205.03
-0.52%
HEALTHCARE · Cap: $365.43B
MYGN
Myriad Genetics Inc
$4.11
-18.29%
HEALTHCARE · Cap: $475.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11178% more annual revenue ($62.82B vs $557.00M). ABBV leads profitability with a 5.8% profit margin vs -41.3%. ABBV appears more attractively valued with a PEG of 0.57. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MYGN
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.6%
Fair Value
$168.19
Current Price
$205.03
$36.84 premium
Intrinsic value data unavailable for MYGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -23.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.8x leaves little room for execution misses.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while MYGN is a turnaround play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 44/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?